{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-24-000032","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.656717+00:00","generated_at":"2026-06-06T08:40:37.746274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued","bullets":["Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).","New Products (Mounjaro, Zepbound) generated $2.49B revenue, up $2.19B YoY; Growth Products $5.27B (+9%).","2024 guidance: revenue $40.4–41.6B; EPS $11.80–12.30; non-GAAP EPS $12.20–12.70.","Pipeline: Zepbound and Jaypirca approved; tirzepatide Phase 2 NASH met primary endpoint; Verzenio Phase 3 mCRPC failed.","Acquisitions of POINT Biopharma and Mablink Biosciences closed; dividend raised 15% for 6th consecutive year."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-24-000032","json":"https://secwatch.observer/filing/0000059478-24-000032.json","markdown":"https://secwatch.observer/filing/0000059478-24-000032.md","text":"https://secwatch.observer/filing/0000059478-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/0000059478-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/lly-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:40:37.746274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f03b6a931bcac37b570a11605b4a6eef8038041","claim":"ELI LILLY & Co reported the quarter and year ended December 31, 2023 results: revenue $9,353.4, net income 2,189.6, EPS 2.42. Guidance initiated.","evidence_excerpt":"on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Fourth Quarter 2023 2022 % Change Revenue $ 9,353.4 $ 7,301.8 28% Net income – Reported 2,189.6 1,937.7 13% Earnings per share – Reported 2.42 2.14 13% Net income – Non-GAAP 2,249.4 1,893.1 19% Earnings per share – Non-GAAP 2.49","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/0000059478-24-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$9,353.4"},{"label":"Net income","value":"2,189.6"},{"label":"EPS","value":"2.42"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}